[前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）：降脂治疗的新机遇]
[Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) New Opportunities of Lipid-Lowering Therapy].
作者信息
Astrakova K S, Ragino Yu I, Shakhtshneider E V, Voevoda M I
机构信息
Institute of Internal and Preventive Medicine, Novosibirsk, Russia.
出版信息
Kardiologiia. 2016 Sep;56(9):84-91. doi: 10.18565/cardio.2016.9.84-91.
In the literature review covered issues opening protein-proprotein convertase, subtilisin/kexin-type9 (PCSK9), its modern terminology, the results of its biochemical, molecular and genetic studies, metabolic regulation, functions and clinical findings in the blood content ofPCSK9 in lipid disorders and clinical pharmacological studies of monoclonal antibodies to this protein for the correction of lipid metabolism of major interest for cardiology and lipidology.
在文献综述中涵盖了有关蛋白原转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）的相关问题，其现代术语，生化、分子和遗传学研究结果，代谢调节，功能以及在脂质紊乱中PCSK9血液含量的临床发现，还有针对该蛋白的单克隆抗体用于纠正脂质代谢的临床药理学研究，这些内容对心脏病学和脂质学具有重要意义。
Zotero 插件